| Document |
Document Title |
|
WO/2017/037639A1 |
The present invention relates to an improved process for the preparation of xylene linked cyclam compounds. More particularly the invention provides a process for preparation of high purity plerixafor which does not involve the use of ex...
|
|
WO/2017/037591A1 |
The present invention relates to a process for preparing amorphous form of Sacubitril / Valsartan sodium salt of Formula-II and pharmaceutical composition comprising thereof.
|
|
WO/2017/032728A1 |
The invention relates to substituted ketoxime benzoylamides of general formula (I) as herbicides. In said formula (I), R1', R2', X, Y and W represent groups such as hydrogen, organic groups such as alkyl, and other groups such as halogen...
|
|
WO/2017/020841A1 |
Disclosed is a pharmaceutical composition containing a specific crystalline powder of LCZ696. The crystalline powder of LCZ696 having a specific powdery feature satisfies a requirement of a preparation process and can be used to produce ...
|
|
WO/2017/012917A1 |
Several methods for the preparation of an amorphous powder comprising a 1:1 stoichiometric mixture of the trisodium salts of Valsartan and Sacubitril are described, as well as the resulting amorphous powder, pharmaceutical compositions c...
|
|
WO/2017/013265A1 |
The present invention relates to compounds according to general formula (I) which are metabolically robust analogues of bioactive lipid mediators derived from omega-3 polyunsaturated fatty acids (n-3 PUFAs).The present invention further ...
|
|
WO/2017/009784A1 |
The present invention describes an amorphous form of trisodium salt of valsartan sacubitril complex and a process for the preparation of same comprising: reacting sacubitril sodium and valsartan disodium or sacubitril and valsartan in th...
|
|
WO/2017/005567A1 |
The invention relates to N-(tetrazole-5-yl)- and N-(triazole-5-yl)aryl carboxamide derivatives of the general formula (I) as herbicides. In said formula (I), V, X, and Z represent groups such as hydrogen, and organic groups such as alkyl...
|
|
WO/2017/005585A1 |
The invention relates to a thermodynamically stable crystal modification of 2-chloro-3-(methylsulfanyl)-n-(1-methyl-1H-tetrazol-5-yl)-4-
(trifluoromethyl)benzamide. This thermodynamically stable crystal modification has particular advant...
|
|
WO/2017/002120A1 |
Compounds useful for selectively eliminating senescent cells, compositions comprising same and uses thereof in treating diseases and disorders in which selective elimination of senescent cells is beneficial are provided. The compounds ar...
|
|
WO/2016/210234A1 |
The present invention relates to metallo-β-lactamase inhibitor compounds of Formula I: (I) and pharmaceutically acceptable salts thereof, wherein Z, RA, X1, X2 and RB are as defined herein. The present invention also relates to composit...
|
|
WO/2016/206101A1 |
The present invention relates to compounds of formula I that are metallo-β-lactamase inhibitors, the synthesis of such compounds, and the use of such compounds for use with β-lactam antibiotics for overcoming resistance.
|
|
WO/2016/198374A1 |
Substituted aromatic sulfonamides of formula (I) pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a di...
|
|
WO/2016/201238A1 |
Solid state forms of trisodium vaisartan : sacubitril, processes for their preparation, pharmaceutical compositions containing such solid state forms and treatment methods using the pharmaceutical compositions are described.
|
|
WO/2016/193190A1 |
The present invention relates to a new class of high relaxivity extracellular gadolinium chelate complexes, to methods of preparing said compounds, and to the use of said compounds as MRI contrast agents.
|
|
WO/2016/192099A1 |
The present invention takes a candesartan cyclic compound as a starting material and performs thereon a three-step reaction of adding tetrazole, hydrolysis and adding a protecting group to directly obtain trityl candesartan without separ...
|
|
WO/2016/189877A1 |
The present invention provides a urea compound or a pharmacologically acceptable salt thereof that has a formyl peptide receptor like 1 (hereinafter may be abbreviated as FPRL1) agonist effect, a pharmaceutical composition containing the...
|
|
WO/2016/185200A1 |
The invention provides a compound which is a peptide derivative of formula (1) as defined in the claims or a salt thereof: RG is H, -CH2-RGA or C1-12 hydrocarbyl optionally substituted with 1 to 4 substituents selected from -OR', -NO2, -...
|
|
WO/2016/187521A1 |
A pharmaceutical formulation includes an antibiotic 5-substituted 1H-tetrazole compound in an amount sufficient to treat a bacterial infection, the antibiotic 5-substituted 1H-tetrazole compound being selected from the group consisting o...
|
|
WO/2016/176689A1 |
Tetrazine non-canonical amino acids, methods for genetic encoding proteins and polypeptides using the tetrazine amino acids, proteins and polypeptides comprising the tetrazine amino acids, and compositions comprising the proteins and pol...
|
|
WO/2016/169902A1 |
The present invention relates to compounds of formula (I), wherein R1' is CH3 R1' is methyl, ethyl, CF3, CH2OH, cyclopropyl or cyano, or R1, and R1 may form together a 1,1-dioxo-tetrahydro-thiophen-3-yl ring; R2 is hydrogen, methyl, ethy...
|
|
WO/2016/153054A1 |
Provided are an efficient method for producing a nitrogen-containing compound or salt thereof to be used in the production of a treatment agent for diseases involving an integrin. Also provided is a production intermediate of the same. A...
|
|
WO/2016/150337A1 |
The present invention relates to a new crystal form of a compound of formula (I), a preparation method and a use thereof. The new crystal form provided in the present invention is stable and has a low hygroscopicity, and a purification p...
|
|
WO/2016/146299A1 |
A process to isolate a compound of Formula (2a) or a salt or solvate thereof, comprising a) reacting a mixture of diastereoisomers of Formulae (2a, 2b) with a basic heterocyclic-aldehyde compound and an optically active amine in the pres...
|
|
WO/2016/149486A1 |
The present invention relates to polymorphic forms of compound 1 or 1a and processes for preparing compound 1 and 1a polymorphs, which are useful as antifungal agents. In particular, the invention seeks to provide a new methodology for p...
|
|
WO/2016/142364A1 |
The invention discloses a method for the preparation of certain 1,5 disubstituted tetrazole and similar compounds starting from certain thioacetamides, which ultimately allows the preparation of these certain 1,5 disubstituted tetrazoles...
|
|
WO/2016/127873A1 |
The present invention provides an isothiocyanate compound and an application thereof. The compound is an aryl substituted isothiocyanate compound that has a structure in the general formula I. The isothiocyanate compound in the present i...
|
|
WO/2016/128541A1 |
The present invention refers to compounds endowed with RNA helicase DDX3 inhibitory activity of formula I and II and their therapeutic use, in particular for the treatment of viral diseases.
|
|
WO/2016/125123A1 |
The amorphous form of trisodium sacubitril valsartan and methods for the preparation thereof are disclosed herein.
|
|
WO/2016/123028A1 |
The present disclosure provides compounds that include a tetrazolone derivative of a carboxyl group of an active agent. This disclosure also relates to pharmaceutical compositions that include these compounds, methods of using these comp...
|
|
WO/2016/115564A1 |
Described are methods for preparing salts of 5-nitrotetrazolate that include reacting aqueous solutions of 5-aminotetrazole, an acid, and sodium nitrite in a continuous flow system at an ambient temperature.
|
|
WO/2016/114634A2 |
The present invention relates to a cyclam derivative compound and a pharmaceutical use thereof. The cyclam derivative compound can alleviate side effects of a drug since the compound enables an efficient drug delivery by selectively reco...
|
|
WO/2016/105172A2 |
The present disclosure relates to a novel method for preparing high-purity gadobutrol. The present disclosure can be easily applied to a large scale production because purity of intermediate can be managed via simple and mild process and...
|
|
WO/2016/091228A1 |
A nitro group-substituted phenyltetrazole of general formula (I) wherein R is selected from the group consisting of: H, C1-C11 alkyl, phenyl- or phenyl- substituted in positions 2, 3, 4 or 5 by one or more electron-acceptor groups and/or...
|
|
WO/2016/088747A1 |
Provided is a novel bactericide, especially a bactericide for agricultural and horticultural use. A hydrazone derivative represented by formula (I), a salt thereof, and a bactericide for agricultural and horticultural use, which contains...
|
|
WO/2016/089208A2 |
The present invention is directed to compounds having formula (I): A-L-R1, wherein A is an anticancer agent comprising at least one group selected from the group comprising OH, NH and NH2 and L is a direct bond or L is a linker and R1 is...
|
|
WO/2016/083605A1 |
The present invention relates to a method of removal of metal ion impurities, such as calcium, from lanthanide metal complexes of macrocyclic chelators. The method uses a scavenger resin to remove metal ions, displaced from chelator, by ...
|
|
WO/2016/077859A1 |
The present disclosure relates to methods and products for labelling, binding and/or detection of lipids. Certain embodiments provide a method of labelling a lipid. The method comprises exposing the lipid to a complex comprising a transi...
|
|
WO/2016/067292A1 |
Energetic nitrogen-rich monomers represented by the general Formula (I); wherein each of X1 and X2 is independently NR or a covalent bond, R is H or C1-4 alkyl, each of T1 and T2 is independently a moiety selected from the group consisti...
|
|
WO/2016/049663A1 |
Novel crystalline Forms of trisodium [3-((1S,3R)-l-biphenyl-4-ylmethyl-3-ethoxycarbonyl-1-butyl carbamoyl) propionate-(S)-3'-methyl-2'-(pentanoyl{2"-(tetrazol-5-ylate)
biphenyl-4'-ylmethyl}amino)butyrate] hydrate, methods for their prepa...
|
|
WO/2016/043462A2 |
The present invention provides a novel method for preparing highly pure calcobutrol using an intermediate (butrol) of gadobutrol without using highly pure gadobutrol. The present invention is capable of obtaining highly pure calcobutrol ...
|
|
WO/2016/037552A1 |
Disclosed are a crystalline ARB-NEPi compound and a preparation method therefor and an application thereof. The ARB-NEPi compound refers to [3-((1S, 3R)-1-biphenyl-4-ylmethyl-3-ethyloxycarbonyl-1-butylcarbamoy
l)propionic acid-(S)-3'-met...
|
|
WO/2016/040179A1 |
A method of reducing radiation exposure of a non-cancerous tissue of a patient diagnosed with a cancer includes administering to the patient an agent capable of competing for binding sites on a surface of the non-cancerous tissue, provid...
|
|
WO/2016/026841A1 |
The present invention relates to new compounds comprising a siderophore moiety as well as a core structure able to chelate a metal ion. Optionally, the compounds may have additionally a moiety with a functional element including a marker...
|
|
WO/2016/022434A1 |
Aspects of the present disclosure include compounds of formula (A) that find use for the treatment of a variety of autoimmune and inflammatory diseases and disorders. Embodiments of the present disclosure also relate to pharmaceutical co...
|
|
WO/2016/015593A1 |
The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or ...
|
|
WO/2016/016272A1 |
The present invention concerns compounds of formula (I):their process of preparation and compositions thereof. The present invention also concerns their use as diagnostic agent in PET imaging.
|
|
WO/2016/016107A1 |
The invention relates to bicyclic arylcarboxylic acid amides of general formula (I) as herbicides. In this formula (I), Z1, Z2, Z3, Z4 and Z5 represent a bond O, S(O)n or a substituted carbon atom. X is a radical such as hydrogen, organi...
|
|
WO/2016/010538A1 |
Compounds represented by formulae I, II, III, and IV including pro-drugs for treprostinil and prostacyclin analogs. Uses include treatment of pulmonary hypertension (PH) or pulmonary arterial hypertension (PAH). The structures of the com...
|
|
WO/2016/005892A1 |
Process for the preparation of a polyazamacrocycle substituted with at least one aryl or heteroaryl group comprising reacting at least one unsubstituted polyazamacrocycle with at least one halogenated aryl or heteroaryl compound. Said po...
|
